actin-binding motif comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
=== Freshwater ecosystems === Whole-lake experiments carried out at the Experimental Lakes Area in Ontario, Canada, have displayed the potential for cage aquaculture to source numerous changes in freshwater ecosystems. Following the initiation of an experimental rainbow trout cage farm in a small boreal lake, dramatic reductions in mysis concentrations associated with a decrease in dissolved oxygen were observed. Significant increases in ammonium and total phosphorus, a driver for eutrophication in freshwater systems, were measured in the hypolimnion of the lake. Annual phosphorus inputs from aquaculture waste exceeded that of natural inputs from atmospheric deposition and inflows, and phytoplankton biomass has had a fourfold annual increase following the initiation of the experimental farm.
Dermcidin is a protein with 110 amino acids that in humans is encoded by the DCD gene. The full-length protein produces derived peptides as proteolysis-inducing factor (PIF) and other anti-microbial peptides, secreted by human eccrine sweat glands onto the skin as a part of the innate host defense of the immune system. PIF is involved in muscular proteolysis.
The musculoskeletal system the organ system that gives humans the ability to move using their muscular and skeletal systems, and is described by the anatomical terms of bone and muscle. It is made up of the bones of the skeleton, muscles, cartilage, tendons, ligaments, joints, and other connective tissue that supports and binds tissues and organs together:
Sources: en.wikipedia.org
In Wolverine and the X-Men and the English dub of the Wolverine anime series, Logan was voiced by Steven Blum, who has voiced the characters across more animated films, series, and video games than any other voice actor. Wolverine has appeared in a variety of Marvel and X-Men video games, and has been the titular lead in six games: Wolverine (1991), Wolverine: Adamantium Rage (1994), X-Men: Wolverine's Rage (2001), the X2 tie-in X2: Wolverine's Revenge (2003), X-Men Origins: Wolverine (2009), a tie-in to the film of the same name, and Marvel's Wolverine (2026), developed by Insomniac Games.
Various 2C drugs show potent anti-inflammatory effects mediated by serotonin 5-HT2A receptor activation. Among these include 2C-I, 2C-B, 2C-H, and 2C-iBu. Others, such as 2C-B-Fly and 2C-T-33, were less effective. 2C-iBu has shown a greater separation between anti-inflammatory effects and psychedelic-like effects in animals than other 2C drugs and is being investigated for possible use as a pharmaceutical drug.
DSC is used widely for examining polymeric materials to determine their thermal transitions. Important thermal transitions include the glass transition temperature (Tg), crystallization temperature (Tc), and melting temperature (Tm). The observed thermal transitions can be utilized to compare materials, although the transitions alone do not uniquely identify composition. The composition of unknown materials may be completed using complementary techniques such as IR spectroscopy. Melting points and glass transition temperatures for most polymers are available from standard compilations, and the method can show polymer degradation by the lowering of the expected melting temperature. Tm depends on the molecular weight of the polymer and thermal history. The percent crystalline content of a polymer can be estimated from the crystallization/melting peaks of the DSC graph using reference heats of fusion found in the literature. DSC can also be used to study thermal degradation of polymers using an approach such as Oxidative Onset Temperature/Time (OOT); however, the user risks contamination of the DSC cell, which can be problematic. Thermogravimetric Analysis (TGA) may be more useful for decomposition behavior determination. Impurities in polymers can be determined by examining thermograms for anomalous peaks, and plasticisers can be detected at their characteristic boiling points.
Sources: en.wikipedia.org
BioLegend was founded by CEO, Gene Lay, D.V.M., who was also the co-founder of PharMingen. In 2011, BioLegend co-developed and introduced Brilliant Violet(TM)-conjugated antibodies, using a novel fluorophore based on Nobel Prize-winning chemistry developed by Sirigen. In 2018, BioLegend introduced TotalSeq™ antibody-oligonucleotide conjugates for use in single cell proteogenomics analysis. BioLegend continued expansion and moved into a new 8-acre campus at BioLegend Way in 2019 with state of the art facilities designed to accommodate up to 1000 employees.
Laboratory testing in the United States is subject to federal regulation. Clinical laboratories performing testing are overseen by the Centers for Medicare and Medicaid Services (CMS) utilizing national standards established under the Clinical Laboratory Improvement Amendments (CLIA). The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) assist CMS in this process. CMS ensures the integrity of laboratories performing testing via inspections and consistent oversight, bolstered with proficiency testing by accredited organizations. CLIA authorizes regulation of laboratories that conduct testing, not the individuals who order the tests or receive test results. All laboratories performing DTC testing must obtain CLIA certification and maintain compliance with national standards.
Firstly, the hydroxylation of compounds begins by cytochrome P450 enzymes. Secondly, hydrophilic moieties join up to the compounds in order to increase water solubility. As a result, the excretion through urine occurs and compounds can be removed. Either CYP4A or CYP4F are the enzymes involved in the downstream metabolism of 1-deoxySLs. It is not yet known which one takes place in the process but, it is more likely to be CYP4F as in mouse experiments this enzyme is responsible for 1-deoxySLs formation.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.